Advertisement
Home Tags Prescription Drugs

Tag: Prescription Drugs

Antipsychotic use is associated with an increased risk for unexpected death among children and youths

Antipsychotics Up Risk for Unexpected Death in Youths

Risk for unexpected deaths increased in higher-dose antipsychotic group versus control group
CT-P13

Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease

CT-P13 is equivalent to reference product in primary outcome; no difference in safety outcomes
For individuals with heart failure

Meds Taken Do Not Vary With ADL Impairment in Heart Failure

Adults with heart failure with impairment in activities of daily living take as many meds as those without
Tamoxifen at a dose of 5 mg/day is associated with a reduced risk for recurrence for women with hormone-sensitive breast intraepithelial neoplasia

SABCS: Low-Dose Tamoxifen Cuts Risk for Breast Dz

More second primary cancers and more frequent menopausal symptoms seen in tamoxifen vs. placebo arm
For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab

SABCS: T-DM1 Cuts Recurrent Invasive HER2+ Breast CA Risk

Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo
For patients with CD30-positive peripheral T-cell lymphoma

ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma

Median progression-free survival improved with A+CHP vs CHOP; similar incidence of adverse events
A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck

FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug

Alemtuzumab label will be updated to include the risk for stroke and arterial dissection
For older patients with untreated chronic lymphocytic leukemia

ASH: Ibrutinib Tops Bendamustine + Rituximab for CLL

Improved progression-free survival with ibrutinib for older adults with untreated CLL
Certain sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
For patients with hereditary angioedema type I or II

Lanadelumab Reduces Attack Rate in Hereditary Angioedema

Significant reduction in attack rate compared with placebo seen for three dose regimens of lanadelumab